Filing Details
- Accession Number:
- 0001209191-24-000929
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-04 21:35:45
- Reporting Period:
- 2024-01-03
- Accepted Time:
- 2024-01-04 21:35:45
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1607678 | Viking Therapeutics Inc. | VKTX | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1264949 | Greg Zante | C/O Viking Therapeutics, Inc. 9920 Pacific Heights Blvd, Suite 350 San Diego CA 92121 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.00001 Per Share | Acquisiton | 2024-01-03 | 28,334 | $0.00 | 188,724 | No | 4 | A | Direct | |
Common Stock, Par Value $0.00001 Per Share | Disposition | 2024-01-03 | 18,233 | $17.40 | 170,491 | No | 4 | F | Direct | |
Common Stock, Par Value $0.00001 Per Share | Acquisiton | 2024-01-03 | 70,000 | $0.00 | 240,491 | No | 4 | A | Direct | |
Common Stock, Par Value $0.00001 Per Share | Disposition | 2024-01-03 | 30,889 | $17.40 | 209,602 | No | 4 | F | Direct | |
Common Stock, Par Value $0.00001 Per Share | Disposition | 2024-01-04 | 13,872 | $18.58 | 195,730 | No | 4 | F | Direct | |
Common Stock, Par Value $0.00001 Per Share | Disposition | 2024-01-04 | 15,000 | $17.90 | 180,730 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | F | Direct | |
No | 4 | A | Direct | |
No | 4 | F | Direct | |
No | 4 | F | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Acquisiton | 2024-01-03 | 155,000 | $0.00 | 155,000 | $17.40 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
155,000 | 2025-01-03 | 2034-01-03 | No | 4 | A | Direct |
Footnotes
- The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2022, 33.34% of which vested on January 3, 2024 upon the achievement of a non-financial performance goal.
- Includes 1,169 shares acquired on May 19, 2023 and 9,942 shares acquired on November 20, 2023 pursuant to the Issuer's 2014 Employee Stock Purchase Plan.
- These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares uponthe vesting of certain shares of common stock subject to certain performance restricted stock units.
- Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award.
- These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.72 to $18.14, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price.
- 25% of the shares subject to the option will vest on each anniversary of the grant date.